Please assess the completion status of the following clinical trial:

Trial Title: Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* BMI ≥ 27 (no lower BMI limit for Type 2 diabetics)~* 70 years of age or less~* Have 2 or more of the following obesity-related co-morbid conditions:~  * Systolic blood pressure 140-160 mmHg (130-160 if diabetic);~ * Diastolic blood pressure 90-100 mmHg (85-100 if diabetic);~ * Requirement for 2 or more medications to achieve control (\<140/90 mmHg)~* Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to achieve control (\<200 mg/dL)~* At lease one of the following metabolic criteria:~  * Fasting blood glucose level \> 100 mg/dL~ * Glucose level \> 140 mg/dL~ * Diagnosis of type 2 diabetes~* Waist circumference ≥ 102 cm for men or ≥88 cm for women~Exclusion Criteria:~* Stroke/MI/unstable cardiovascular disease within 6 months~* Clinically significant renal, hepatic or psychiatric disease~* Unstable thyroid disease or replacement therapy~* Nephrolithiasis~* Obesity of known genetic or endocrine origin~* Participation in a formal weight loss program or lifestyle intervention~* Glaucoma or intraocular pressure~* Pregnancy or breastfeeding~* Drug or Alcohol abuse~* Smoking cessation within previous 3 months or plans to quit smoking during study~* Eating disorders~* Cholelithiasis within past 6 months~* Excluded medications~* Type 1 diabetes or use of any antidiabetic medication other than metformin~* Previous bariatric surgery~* Bipolar disorder or psychosis~* Steroid hormone therapy~* Systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg~* Creatinine clearance \< 60 mL/minute

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 Top (Type: EXPERIMENTAL): high dose experimental treatment
- VI-0521 Mid (Type: EXPERIMENTAL): mid dose experimental treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).